Uy Ear
Stock Analyst at Mizuho
(3.97)
# 600
Out of 5,055 analysts
71
Total ratings
46.51%
Success rate
15.08%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $18.81 | +38.22% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $29.04 | +54.96% | 6 | Oct 27, 2025 | |
| QURE uniQure | Maintains: Outperform | $30 → $60 | $29.88 | +100.80% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $24.79 | +125.90% | 2 | Sep 24, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $24.02 | -0.08% | 14 | Aug 7, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $18.54 | +358.47% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $25.00 | -16.00% | 14 | Feb 26, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $3.95 | -74.68% | 1 | Dec 5, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $7.47 | +435.48% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $7.22 | +218.56% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $144.86 | -3.35% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $195.93 | -79.58% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.31 | +332.90% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.19 | +152.10% | 2 | Mar 1, 2023 |
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $18.81
Upside: +38.22%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $29.04
Upside: +54.96%
uniQure
Sep 25, 2025
Maintains: Outperform
Price Target: $30 → $60
Current: $29.88
Upside: +100.80%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $24.79
Upside: +125.90%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $24.02
Upside: -0.08%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $18.54
Upside: +358.47%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $25.00
Upside: -16.00%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $3.95
Upside: -74.68%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $7.47
Upside: +435.48%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $7.22
Upside: +218.56%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $144.86
Upside: -3.35%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $195.93
Upside: -79.58%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.31
Upside: +332.90%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.19
Upside: +152.10%